Decision Diagnostics and Subsidiaries Elaborate on the Patent Infringement Lawsuit Against Johnson & Johnson and Two of Its Divisions - Seite 2

The company's nationally prominent patent legal counsel, responsible for a series of conclusive successive legal victories over the last three years against J&J/Lifescan, has strongly recommended pursuit of this legal action after extensive review of all the related patents. It is their informed opinion and that of other experts that J&J/Lifescan's patent violations are so clear and so egregious that there is no other course for our companies to pursue. The companies have filed for, and are entitled to, a court awarded compensation of at least $400 million, and perhaps as much as $700 million.

Mr. Berman concluded, "J&J/Lifescan has prosecuted its illicit and extra-legal campaign against our products and company for 4+ years. We have weathered every storm and won each of the critical legal confrontations. We will continue to battle and win on those fronts. This filing against J&J/Lifescan will no doubt be cause for personal vindication amongst our shareholders. Although, our actions do possess a semblance of retributive justice, it is greatly disappointing that an entity of their magnitude would be reduced to appropriating the technological breakthroughs of others to achieve their own financial objectives.

"The judgment from this litigation will undoubtedly properly readjust their attainment of those objectives. It is important to note that although amply justified, we will not pursue similar underhanded and legally questionable threats of intimidation against their customers or the customers of their customers should these entities purchase the Lifescan patent violated product during the course of this litigation, as Lifescan/J&J repeatedly did to our customers and the customers of our customers. We have always tried to maintain higher standards of integrity and expect to continue to do so."

Forward-Looking Statements:
This release contains the Company's forward-looking statements which are based on management's current expectations and assumptions as of March 14, 2016, regarding the Company's business and performance, its prospects, current factors, the economy and other future conditions and forecasts of future events, circumstances and results.

CONTACT INFORMATION
Decision Diagnostics Corp.
Keith Berman
[phone]
[e-mail]
www.decisiondiagnostics.com
www.pharmatechdirect.com